Abstract 155P
Background
Circulating tumor cells (CTCs) are cells of epithelial origin from clones of the primary tumor, located in the G0 phase and found in the peripheral blood of patients with various forms of solid cancer. Currently, CTCs are found in breast cancer, prostate cancer, colorectal cancer, and their number is used as an independent prognostic factor. The detection of CTCs in various tumors can help in the study of the process of metastasis and the biology of tumor growth. The aim of the work is to establish the presence and frequency of CTCs in the peripheral blood of patients with cancer in the bladder.
Methods
41 peripheral blood samples from patients with verified bladder cancer of stage III-IV were analyzed. The blood was taken into vacuum tubes with anticoagulant. The selection of the CTC on the density gradient. From the obtained material, 2 cytological preparations were prepared on the cytocentrifuge of Hospitex diagnostics (Italy) and stained according to Romanovsky. Calculation of the CTC at the light-optical level using a Zeiss Primo Star microscope (Germany). The final result was the total number of detected CTCs. The control group consisted of peripheral blood samples from 10 patients without cancer.
Results
CTCs were detected in 46.3% of cases (19 samples) in the amount of 1-14 cells. In the morphological structure of primary tumors, according to the results of histological examination, the samples were divided as follows: squamous cell carcinoma – 1, adenocarcinoma (metastasis of cervical cancer) – 1, urothelial carcinoma – 17. The calculation of the CTC by morphological forms of the tumor showed that 4-6 cells were detected in squamous cell carcinoma, 6 cells in adenocarcinoma, and 2 - 14 cells in urothelial carcinoma (2-4 cells in the II st., 7-14 cells in the IIII st.; Xsr=2.43). In the blood samples of the control patients, CTCs were also not detected.
Conclusions
The presence of CTC in the peripheral blood of patients with bladder cancer was detected in 46.3% of cases and has differences depending on the morphological form of the tumor, which requires further study. The largest number of CTCs in our study was revealed in the transitional cell (urothelial) morphological form of cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
265P - Tumor-agonistic genomic profiling
Presenter: Naomi Hayashi
Session: Poster viewing 03
266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Presenter: Xuchao Zhang
Session: Poster viewing 03
267P - Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Presenter: Amit Rauthan
Session: Poster viewing 03
269P - MET alterations in EGFR mutated NSCLC: A lesser known evil
Presenter: Mansi Sharma
Session: Poster viewing 03
271P - Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Presenter: Kaushik R
Session: Poster viewing 03